°£Áú Ä¡·áÁ¦ ½ÃÀå : ¼¼´ë À¯Çüº°, Ç×°£ÁúÁ¦ À¯Çüº°, À¯Åë ä³Îº°, Áö¿ªº°(2025-2033³â)
Epilepsy Drugs Market by Generation Type, Anti-Epileptics Drugs Type, Distribution Channel, and Region 2025-2033
»óǰÄÚµå : 1636006
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 135 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,130,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,507,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 6,884,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

°£Áú Ä¡·áÁ¦ ½ÃÀåÀÇ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 25¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö ½ÃÀå ±Ô¸ð°¡ 46¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025-2033³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 6.87%¿¡ ´ÞÇÒ °ÍÀ¸·Î Àü¸ÁÇϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è °£Áú À¯º´·ü Áõ°¡, ¾à¹° °³¹ß ¹× ±â¼ú Çõ½ÅÀÇ È¹±âÀûÀÎ ¹ßÀü, °£Áú ¹× Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀÎ½Ä °³¼±, ÀÇ·áºñ ÁöÃâ Áõ°¡ ¹× Ä¡·á Á¢±Ù¼º °³¼±ÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÀϺÎÀÔ´Ï´Ù.

°£Áú Ä¡·áÁ¦´Â °£Áú Ä¡·á¿¡ »ç¿ëµÇ´Â ¾à¹°À» ¸»Çϸç, °£ÁúÀº ¿¹ÃøÇÒ ¼ö ¾ø°í, À¯¹ßµÇÁö ¾ÊÀ¸¸ç, Àç¹ß¼º ¹ßÀÛÀ» À¯¹ßÇÏ´Â ÁßÃ߽Űæ°è(CNS) ÁúȯÀÔ´Ï´Ù. °£ÁúÀº ´Ù¾çÇÑ Á¤½ÅÀû, ½ÅüÀû ±â´É¿¡ ¿µÇâÀ» ¹ÌÄ¡¸ç °©ÀÛ½º·¯¿î Çൿ º¯È­, °¨°¢, ÀÇ½Ä »ó½Ç, ½É°¢ÇÑ Á¤½ÅÀû °íÅëÀ» À¯¹ßÇÕ´Ï´Ù. °£ÁúÄ¡·áÁ¦´Â Á¤Á¦, ĸ½¶Á¦, ¾×Á¦, ½Ã·´Á¦ µî 1¼¼´ë, 2¼¼´ë, 3¼¼´ë Ç×°£ÁúÁ¦(AED)°¡ ÀÖÀ¸¸ç, °æ±¸Åõ¿©, Á¤¸ÆÅõ¿©, ±ÙÀ°Åõ¿©°¡ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. °£Áú Ä¡·áÁ¦´Â ºÎºÐ¹ßÀÛ, ³­Ä¡¼º ¹ßÀÛ, È¥ÇÕ¹ßÀÛ, °­Á÷°£´ë¹ßÀÛ, ±Þ¼º¹Ýº¹¹ßÀÛ µî ´Ù¾çÇÑ ¹ßÀÛÀÇ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. °£Áú Ä¡·áÁ¦´Â ¾ÈÀüÇÏ°í ³»¾à¼ºÀÌ ÁÁÀ¸¸ç »ý¸íÀ» À§ÇùÇÏ´Â ºÎÀÛ¿ëÀ» ¿¹¹æÇϰí ÀÎÁö±â´É¿¡ ¹ÌÄ¡´Â ¾Ç¿µÇâÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÇöÀç, ½Å°æ Áúȯ, Ãâ»ê °ü·Ã ºÎ»ó, °¨¿°, ¾à¹° ³²¿ë, ±³Åë »ç°í µîÀÇ Áõ°¡·Î ÀÎÇØ °£Áú À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. °£Áú Ä¡·áÁ¦´Â ¹ßÀÛ Á¦°Å, ¹ßÀÛ ºóµµ °¨¼Ò, Àå±â Ä¡·á¿¡ µû¸¥ ºÎÀÛ¿ëÀ» ÇÇÇϱâ À§ÇØ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, ȯÀÚ°¡ Á¤»óÀûÀÎ ½É¸® »çȸÀû, Á÷¾÷Àû Ȱµ¿À» ȸº¹Çϰí Á¤»óÀûÀÎ »ýȰ ¹æ½ÄÀ» À¯ÁöÇϵµ·Ï µ½°í ÀÖ½À´Ï´Ù. ¿©±â¿¡ ¹ßÀÛÀÇ ¿øÀÎÀÌ µÇ´Â ³úÁ¾¾ç°ú °°Àº ½É°¢ÇÑ Áúº´¿¡ °É¸®±â ½¬¿î ³ë·É Àα¸ÀÇ Áõ°¡°¡ ¶Ç ´Ù¸¥ Å« ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àú·ÅÇÑ °¡°Ý, ºÎÀÛ¿ëÀÌ Àû°í ³»¾à¼º ¹× À¯È¿¼ºÀÌ °³¼±µÈ ½Å¾à ¹× ÷´Ü ÀǾàǰ °³¹ßÀ» À§ÇÑ ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿ÀÌ ÇöÀç ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, Ç÷û ¾à¹° ³óµµÀÇ º¯µ¿À» ÃÖ¼ÒÈ­Çϸ鼭 Åõ¿© °£°ÝÀ» ´Ã¸± ¼ö ÀÖ´Â ¼­¹æÇü(ER) Á¦Á¦ÀÇ °³¹ßÀº ¼Ó¹æÇü(IR) Á¦Á¦ ´ëºñ È¿´É°ú º¹¾à ¼øÀÀµµ¸¦ Çâ»ó½ÃÄÑ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áúȯ¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀ» ³ôÀ̰í, ¿¬±¸¸¦ ÃËÁøÇϰí, ´õ ³ªÀº Ä¡·á ¿É¼ÇÀ» ½Å¼ÓÇÏ°Ô Á¦°øÇÔÀ¸·Î½á Àû±ØÀûÀÎ Áö¿øÀ» Á¦°øÇϱâ À§ÇÑ ´Ù¾çÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºêÀÇ ½ÃÇàÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ½Å¾à ½ÂÀÎ Áõ°¡, ÀÇ·á ÀÎÇÁ¶ó ½Ã¼³ÀÇ ±Þ¼ÓÇÑ °³¼±, ½Å°æ ÁúȯÀÇ Ä¡·á¹ý¿¡ ´ëÇÑ ´ëÁßÀÇ ÀÎ½Ä Áõ°¡, °£Áú¿¡ ´ëÇÑ ³«Àΰ¨ °¨¼Ò µîÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ °£Áú Ä¡·áÁ¦ ½ÃÀå

Á¦6Àå ½ÃÀå ³»¿ª : ¼¼´ë À¯Çüº°

Á¦7Àå ½ÃÀå ³»¿ª : Ç×°£ÁúÁ¦ À¯Çüº°

Á¦8Àå ½ÃÀå ³»¿ª : À¯Åë ä³Îº°

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

Á¦10Àå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global epilepsy drugs market size reached USD 2.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.6 Billion by 2033, exhibiting a growth rate (CAGR) of 6.87% during 2025-2033. The increasing prevalence of epilepsy worldwide, significant advancements in drug development and innovation, growing awareness about epilepsy and its treatment options, and rising healthcare expenditure and improving access to treatment are some of the key factors propelling the market growth.

Epilepsy drugs refer to medications used for treating epilepsy, a central nervous system (CNS) disorder that causes unpredictive, unprovoked, and recurrent episodes of seizures. Epilepsy affects various mental and physical functions causing sudden behavioral changes, sensations, loss of awareness, and severe emotional distress. Its medication includes first-, second-, and third-generation anti-epileptic drugs (AEDs), such as tablets, capsules, liquids, and syrups that are administered through oral, intravenous (IV), and intramuscular routes. Epilepsy drugs are widely used to treat various seizures, including partial onset, hard-to-treat, mixed, tonic-clonic, and acute repetitive seizures. Epilepsy drugs are safe, offer better tolerability, prevent life-threatening adverse effects, and minimize the negative impact on the cognitive functions.

At present, the rising prevalence of epilepsy due to increasing incidences of neurological disorders, birth-related injuries, infections, substance abuse, and road injuries is one of the primary factors driving the market growth. Epilepsy drugs are widely used to eliminate seizures, reduce their frequency, and evade the adverse effects associated with long-term treatments, thus helping patients in restoring their usual psychosocial and vocational activities and maintaining a normal lifestyle. In addition to this, the rising geriatric population that is prone to developing critical ailments, such as brain cancer, that can cause seizures, is acting as another major growth-inducing factor. Furthermore, extensive research and development (R&D) activities toward developing new and advanced drugs that are affordable and provide improved tolerability and efficacy with fewer side effects are currently positively influencing the market growth. Apart from this, the recent development of extended-release (ER) drug formulations that allow longer dosing intervals while minimizing the fluctuations in serum drug levels, thus improving efficacy and adherence as compared to immediate-release (IR) drugs, is facilitating the market growth. Moreover, the implementation of various government initiatives to educate the masses about the disorder, promote research, and provide active support by expediting better treatment options are propelling the market growth. Other factors, including the rising approval of novel drugs, rapid improvements in healthcare infrastructural facilities, increasing public awareness regarding the available treatments of neurological disorders, and the decreasing stigma associated with epilepsy, are anticipated to drive the market toward growth.

Key Market Segmentation:

Generation Type Insights

First Generation Drugs

Phenytoin

Carbamazepine

Oxcarbazepine

Valproate

Ethosuximide

Primidone

Phenobarbital

Second Generation Drugs

Levetiracetam

Lamotrigine

Topiramate

Pregabalin

Rufinamide

Zonisamide

Third Generation Drugs

Lacosamide

Perampanel

Eslicarbazepine Acetate

Ezogabine/Retigabine

The report has also provided a detailed breakup and analysis of the epilepsy drugs market based on the generation type. This includes first generation drugs (phenytoin, carbamazepine, oxcarbazepine, valproate, ethosuximide, primidone, and phenobarbital), second generation drugs (levetiracetam, lamotrigine, topiramate, pregabalin, rufinamide, and zonisamide), and third generation drugs (lacosamide, perampanel, eslicarbazepine acetate, and ezogabine/retigabine). According to the report, second generation drugs represented the largest segment.

Anti-Epileptics Drugs Type Insights

Narrow-Spectrum AEDs

Broad-Spectrum AEDs

Distribution Channel Insights

Hospital Pharmacy

Pharmacy Stores

Others

Regional Insights:

Key Questions Answered in This Report:

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Epilepsy Drugs Market

6 Market Breakup by Generation Type

7 Market Breakup by Anti-Epileptics Drugs Type

8 Market Breakup by Distribution Channel

9 Market Breakup by Region

10 Drivers, Restraints, and Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â